支气管缩剂在支气管缩的研究 (DIBS):实用性,多中心,安慰剂控制,三臂,双盲,随机对照试验的协议,研究支气管缩剂在预防支气管缩的恶化
Miranda Morton1, Nina Wilson2, Tara Marie Homer3
1Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.
BMJ open
|August 10, 2023
概括
这项研究调查了吸入的双重支气管扩展剂,有或没有吸入的皮质类固醇,是否可以减少12个月的支气管切开症的成年人接受抗生素治疗的恶化.
科学领域:
- 肺部病理学 肺部病理学
- 临床试验 临床试验
- 呼吸系统医学 呼吸系统医学
背景情况:
- 支气管病是一种慢性肺部疾病,其特征是支气管扩张,炎症,感染和频繁的恶化.
- 经常出现的恶化会加剧疾病的严重程度,增加住院治疗,降低生活质量,增加死亡风险.
- 由于支气管病的患病率日益增加,需要进行高质量的研究和批准的支气管病治疗方法.
研究的目的:
- 为了确定吸入的双重支气管扩展剂 (长效β-激动剂和长效肌酸抗剂) 是否可以减少支气管支气管病的抗生素治疗恶化.
- 评估单独使用双支气管扩展剂治疗的疗效与与吸入性皮质类固醇联合使用的疗效.
- 为了评估这些疗法在12个月的治疗期间的影响.
主要方法:
- 一个多中心,实用,双盲,随机对照试验,涉及600名成年患者,CT确诊的支气管支障.
- 参与者被随机分配到接受吸入双疗法 (LABA+LAMA),三重疗法 (LABA+LAMA+ICS) 或安慰剂,比例为2:2:1.
- 主要结局指标是12个月内需要抗生素治疗的协议定义恶化病例数量.
主要成果:
- 该研究目前正在招募,结果正在等待.
- 目前正在进行数据收集和分析,以评估主要结果.
- 该试验旨在提供关于吸入支气管扩展剂在治疗支气管切除症恶化中的有效性的强有力的证据.
结论:
- 这项试验将提供关于吸入支气管扩展剂治疗支气管支气管病的有效性的关键数据.
- 预计这些发现将为临床实践提供信息,并可能导致新的治疗指南.
- 结果将通过同行评审的出版物,会议和公众宣传进行传播.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...